The Latest Breaking News from Regenxbio

Hunter Syndrome Gene Therapy Halted by FDA After Spine Scans Show Small Masses in Five Children

FDA placed REGENXBIO's RGX-121 on clinical hold after spine MRIs showed nodules or cysts in five Hunter syndrome trial participants.

Medical Daily · Aug 25

Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date

On Friday, REGENXBIO Inc. (NASDAQ:RGNX) shared new data from the Phase 1/2/3 CAMPSIITE trial of clemidsogene lanparvovec (RGX-121) for the treatment of patients with Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome, at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025.

Benzinga · Sep 5, 2025

FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year

The U.S. Food and Drug Administration (FDA) on Monday extended its review timeline for REGENXBIO Inc.’s (NASDAQ:RGNX) Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121) for Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome.

Benzinga · Aug 19, 2025

Expert Ratings for Regenxbio

Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · May 24, 2022

5 Value Stocks In The Healthcare Sector

What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Benzinga · May 16, 2022

Expert Ratings for Regenxbio

Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings within the last quarter:

Benzinga · May 5, 2022

Regenxbio's Return On Capital Employed Overview

According to Benzinga Pro, during Q4, Regenxbio (NASDAQ:RGNX) earned $294.02 million, a 603.42% increase from the preceding quarter. Regenxbio also posted a total of $398.65 million in sales, a 1195.47% increase since Q3.

Benzinga · Mar 7, 2022

Expert Ratings For Regenxbio

Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · Mar 2, 2022

Regenxbio: Q4 Earnings Insights

Regenxbio (NASDAQ:RGNX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Regenxbio beat estimated earnings by 41.61%, reporting an EPS of $6.67 versus an estimate of $4.71.

Benzinga · Mar 1, 2022

Earnings Preview: Regenxbio

Regenxbio (NASDAQ:RGNX) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts estimate that Regenxbio will report an earnings per share (EPS) of $4.71.

Benzinga · Feb 28, 2022